e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
IPF: from bench to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Differential metabolism of hyaluronic acid in patients with idiopathic pulmonary fibrosis
Katrin Esther Hostettler Haack (Basel, Switzerland), Katrin Hostettler, Eleni Papakonstantinou, Ioannis Klagas, Ioannis Bonovolias, Chistopher Lambers, Michael Tamm, Michael Roth
Source:
International Congress 2015 – IPF: from bench to bedside
Session:
IPF: from bench to bedside
Session type:
Poster Discussion
Number:
3055
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Katrin Esther Hostettler Haack (Basel, Switzerland), Katrin Hostettler, Eleni Papakonstantinou, Ioannis Klagas, Ioannis Bonovolias, Chistopher Lambers, Michael Tamm, Michael Roth. Differential metabolism of hyaluronic acid in patients with idiopathic pulmonary fibrosis. Eur Respir J 2015; 46: Suppl. 59, 3055
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Effect of nintedanib on hyaluronic acid metabolism in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip
Source: ERS Lung Science Conference 2021
Year: 2021
Idiopathic pulmonary fibrosis
Source: Eur Respir Monogr 2015; 68: 50-63
Year: 2015
Idiopathic pulmonary fibrosis
Source: School Course 2014 - Interstitial lung diseases
Year: 2014
Idiopathic pulmonary fibrosis
Source: Eur Respir Monogr 2013; 62: 37-53
Year: 2013
Idiopathic pulmonary fibrosis
Source: International Congress 2018 – State of the art session: Interstitial lung diseases
Year: 2018
Exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2016 – Russia Session
Year: 2016
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 695-696
Year: 2010
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 35: 821-829
Year: 2010
Ectopic subpleural fat deposition in idiopathic pulmonary fibrosis correlates with radiographic extension of fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Clinical features of patients with idiopathic pulmonary upper lobe-dominant fibrosis
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Hyaluronic acid is significantly increased in idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 604s
Year: 2006
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Pulmonary hypertension in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Idiopathic pulmonary fibrosis and pirfenidone
Source: Eur Respir J 2010; 35: 728-729
Year: 2010
Role of MUC4 in idiopathic pulmonary fibrosis
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept